Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose?

Recent Results in Cancer Research

Volumn 194, Issue , 2013, Pages 561-566

  Kulkarni, Harshad R ^a   Prasad, Vikas ^a   Schuchardt, Christiane ^a   Baum, Richard P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LUTETIUM TETRAXETAN OCTREOTIDE LU 177; LUTETIUM TETRAXETAN OCTREOTIDE[3 TYROSINE] LU 177; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSIMETRY; ERYTHROCYTE COUNT; ERYTHROPENIA; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MEAN RESIDENCE TIME; NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE THERAPY; SPLEEN; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84867052224     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-27994-2_33     Document Type: Article

References (7)

1. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M (2004) Peptide receptor radionuclide therapy. Ann N Y Acad Sci 1014:234-245 (Pubitemid 38594811)
2. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130
3. Reubi JC, Kvols L, Krenning EP, Lamberts SWJ (1990) Distribution of somatostatin receptor in normal and tumour tissue. Metabolism 30(suppl 2):78-81 (Pubitemid 20286341)
4. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, Figueiredo JL, Kohler RH, Chudnovskiy A, Waterman P, Aikawa E, Mempel TR, Libby P, Weissleder R, Pittet MJ (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325:612-616
5. Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP (2007) Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm 22:406-416 (Pubitemid 47067899)
6. Weinmann M, Becker G, Einsele H, Bamberg M (2001) Clinical indications and biological mechanisms of splenic irradiation in chronic leukaemias and myeloproliferative disorders. Radiother Oncol 58:235-246 (Pubitemid 32181856)
7. van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723-734 (Pubitemid 47123757)